Acquiring Company
Slate Medicines
Acquired Company
Fulcrum Therapeutics
RaleighCambridgeBiotechnologyHealth CareBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Slate Medicines and Fulcrum Therapeutics have announced a definitive all-stock merger agreement to form a new biotechnology entity. The combined company will focus on next-generation treatments for migraines and is expected to begin trading on Nasdaq. The merger is anticipated to close in the fourth quarter of 2026, pending various approvals.
Don't miss Slate Medicines's next move
Get an email the moment Slate Medicines makes an acquisition, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
M&A Insights
Based on deal dataFrequently asked
Who acquired Fulcrum Therapeutics?
Fulcrum Therapeutics was acquired by Slate Medicines, based in Raleigh. The deal was reported on August 17, 2026. Slate Medicines, Inc. is a biotech company focused on advancing next generation therapeutics for migraine and other headache disorders. Slate Medicines is privately held and operates in Biotechnology.
When did Slate Medicines acquire Fulcrum Therapeutics?
Slate Medicines's acquisition of Fulcrum Therapeutics was reported on August 17, 2026. Slate Medicines and Fulcrum Therapeutics have announced a definitive all-stock merger agreement to form a new biotechnology entity. The combined company will focus on next-generation treatments for migraines and is expected to begin trading on Nasdaq. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Fulcrum Therapeutics do?
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases. It is publicly traded (FULC), operating in Biotechnology, and is based in Cambridge.